3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Breast
1
Conditions
Breast Neoplasms
24
Carcinoma, Non-Small-Cell Lung
12
Precursor Cell Lymphoblastic Leukemia-Lymphoma
6
Pancreatic Neoplasms
5
Neoplasms
5
Lung Neoplasms
5
Leukemia, Myeloid, Acute
5
Triple Negative Breast Neoplasms
4
Melanoma
4
Leukemia, Myelomonocytic, Chronic
4
Carcinoma, Renal Cell
4
Breast Diseases
4
Urinary Bladder Neoplasms
3
Thoracic Neoplasms
3
Respiratory Tract Neoplasms
3
Lymphoma
3
Lung Diseases
3
Leukemia, Myelomonocytic, Acute
3
Kidney Neoplasms
3
Fallopian Tube Neoplasms
3
Congenital Abnormalities
3
Colonic Neoplasms
3
Bronchial Neoplasms
3
Vulvar Neoplasms
2
Vaginal Neoplasms
2
Uveal Melanoma
2
Uterine Cervical Neoplasms
2
Sezary Syndrome
2
Recurrence
2
Rectal Neoplasms
2
Interventions
Carboplatin
12
Pemetrexed
8
pembrolizumab
4
Paclitaxel
4
Cisplatin
4
durvalumab
3
Radiosurgery
3
Gemcitabine
3
selpercatinib
2
pralsetinib
2
osimertinib
2
camrelizumab
2
atezolizumab
2
Docetaxel
2
repotrectinib
1
motexafin gadolinium
1
exemestane
1
entinostat
1
ceralasertib
1
cemiplimab
1
belinostat
1
belagenpumatucel L
1
alectinib
1
Vinorelbine
1
Tyrosine Kinase Inhibitors
1
TNFSF10 protein, human
1
Radiotherapy
1
Platinum Compounds
1
Oncolytic Virotherapy
1
Nivolumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Carcinoma, Bronchogenic
×
entinostat
×
Clear all
NCT01594398
2021-11-19
ENCORE110
Syndax Pharmaceuticals
Phase 1
Completed
14 enrolled